# Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

> **NCT05624749** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 288 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** ianalumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05624749
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-21
- **Primary completion:** 2027-04-12
- **Final completion:** 2029-04-09
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624749, "Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05624749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*